Literature DB >> 12355475

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Michele F Doran1, Cynthia S Crowson, Gregory R Pond, W Michael O'Fallon, Sherine E Gabriel.   

Abstract

OBJECTIVE: A high frequency of infections complicating rheumatoid arthritis (RA) has been described in reports of case series. This retrospective longitudinal cohort study was undertaken to compare the frequency of infections in a population-based incidence cohort of RA patients with that in a group of individuals without RA from the same population.
METHODS: RA patients included all members of an incidence cohort of Rochester, Minnesota residents ages >or=18 years who were first diagnosed as having RA between 1955 and 1994. One age- and sex-matched subject without RA was selected for each patient with RA. Study subjects were followed up by review of their entire medical record until death, migration from the area, or study end (January 1, 2000), and details of all documented infections, along with information on potential risk factors for infection, were recorded. Hazard ratios for infections were estimated using stratified Andersen-Gill proportional hazards models, with adjustment for potential confounders.
RESULTS: The 609 RA patients and 609 non-RA study subjects (mean age 58.0 years; 73.1% female) were followed up for a mean of 12.7 years and 15.0 years, respectively, reflecting higher mortality among the group with RA. Hazards ratios for objectively confirmed infections, infections requiring hospitalization, and any documented infection in patients with RA were 1.70 (95% confidence interval [95% CI] 1.42-2.03), 1.83 (95% CI 1.52-2.21), and 1.45 (95% CI 1.29-1.64), respectively, after adjustment for age, sex, smoking status, leukopenia, corticosteroid use, and diabetes mellitus. Sites of infection with the highest risk ratios were bone, joints, skin, soft tissues, and the respiratory tract.
CONCLUSION: In this study, patients with RA were at increased risk of developing infections compared with non-RA subjects. This may be due to immunomodulatory effects of RA, or to agents with immunosuppressive effects used in its treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12355475     DOI: 10.1002/art.10524

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  309 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

Review 3.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

4.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

5.  Anti-tumor necrosis factor therapy and influenza: keeping it in perspective.

Authors:  Matt Shale; Markus Czub; Gilaad G Kaplan; Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 6.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

7.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 8.  Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.

Authors:  Matthew E Falagas; Katerina G Manta; Gregoria I Betsi; Georgios Pappas
Journal:  Clin Rheumatol       Date:  2006-12-21       Impact factor: 2.980

Review 9.  Tumor necrosis factor inhibitors and infection complications.

Authors:  Monica Crawford; Jeffrey R Curtis
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

10.  Initiation of rheumatoid arthritis treatments and the risk of serious infections.

Authors:  Carlos G Grijalva; Lisa Kaltenbach; Patrick G Arbogast; Edward F Mitchel; Marie R Griffin
Journal:  Rheumatology (Oxford)       Date:  2009-11-11       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.